{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:49:42Z","timestamp":1789148982731,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Palmoplantar Pustulosis (PPP) is a rare chronic skin disorder characterized by recurrent sterile pustules on palms and soles, leading to significant pain and functional impairment. Treatments include topical medications, phototherapy, systemic treatments, and biologics, but nonconclusive strategy exists. Here we report a case of a 66-year-old Chinese woman who developed refractory PPP after COVID-19 vaccination, characterized by painful, itchy pustules on her hands and feet. Initial treatments such as topical corticosteroids, calcipotriol, methotrexate, and cyclosporine were ineffective. Due to potential hypersensitivity reactions post-vaccination and elevated Immunoglobulin (Ig)E levels, anti-IgE therapy was administrated. Omalizumab treatment resulted some improvement, but noticeable symptoms persisted. Upon switching to upadacitinib, the patient experienced rapid and complete resolution of pustules and desquamation, with continued symptom control and no severe adverse reactions over a year. Throughout the treatment, clinical symptoms and the patient\u2019s quality of life were assessed using the Palmoplantar Pustular Psoriasis Area and Severity Index (PPP ASI), the Palmoplantar Pustulosis Physician Global Assessment (PPP PGA), and the Dermatology Life Quality Index (DLQI). Serum IgE and food-specific (FS)-IgG4 levels were monitored. Additionally, reductions in cytokine levels (interleukin (IL)-4, IL-13, IL-25, IL-33, and tumor necrosis factor (TNF)-\u03b1) were observed after upadacitinib treatment. This case highlights the potential of upadacitinib, as an effective treatment for PPP, emphasizing the need for further research into targeted therapies addressing multiple signaling pathways involved in PPP\u2019s pathogenesis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1476584","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:46:33Z","timestamp":1741589193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib"],"prefix":"10.3389","volume":"16","author":[{"given":"Boyun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.043","article-title":"Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials","volume":"89","author":"Spencer","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-00745-6","article-title":"Clinical characteristics of Japanese patients with palmoplantar pustulosis","volume":"39","author":"Yamamoto","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00503-5","article-title":"Palmoplantar pustulosis: recent advances in etiopathogenesis and emerging treatments","volume":"21","author":"Misiak-Galazka","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"Cd011628","DOI":"10.1002\/14651858.CD011628.pub2","article-title":"Interventions for chronic palmoplantar pustulosis","volume":"1","author":"Obeid","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3275","article-title":"Association of clinical and demographic factors with the severity of palmoplantar pustulosis","volume":"156","author":"Benzian-Olsson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S421299","article-title":"Refractory palmoplantar pustulosis successfully treated with JAK inhibitor tofacitinib: A case series","volume":"16","author":"Xu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02669-w","article-title":"The epidemiology of palmoplantar pustulosis: an analysis of multiple health insurance claims and electronic health records databases","volume":"40","author":"Ramcharran","year":"2023","journal-title":"Adv Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.03.003","article-title":"Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism","volume":"98","author":"Murakami","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S240607","article-title":"Diagnosis, screening and treatment of patients with palmoplantar pustulosis (PPP): A review of current practices and recommendations","volume":"13","author":"Freitas","year":"2020","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02153.x","article-title":"Evaluation of time-dependent response to psoralen plus UVA (PUVA) treatment with topical 8-methoxypsoralen (8-MOP) gel in palmoplantar dermatoses","volume":"44","author":"Engin","year":"2005","journal-title":"Int J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.1109","article-title":"A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis","volume":"20","author":"Hayama","year":"2010","journal-title":"Eur J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: A randomized clinical trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16132","article-title":"Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study","volume":"48","author":"Okubo","year":"2021","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"117860","DOI":"10.1016\/j.biopha.2025.117860","article-title":"the potential accelerator of comorbid psoriasis and atherosclerosis","volume":"183","author":"Wang","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2016.175.issue-1","article-title":"IgE and Fc\u03f5RI are highly expressed on innate cells in psoriasis","volume":"175","author":"Yan","year":"2016","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15551","article-title":"Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: A case report and review of the literature","volume":"22","author":"Abdelmaksoud","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15359","article-title":"Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria","volume":"35","author":"Diluvio","year":"2022","journal-title":"Dermatol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13161","article-title":"Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function","volume":"48","author":"Abdel-Gadir","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.168","article-title":"Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis","volume":"146","author":"Lillis","year":"2010","journal-title":"Arch Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09819.x","article-title":"Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis","volume":"163","author":"Hagforsen","year":"2010","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01325.x","article-title":"Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum","volume":"20","author":"Murakami","year":"2011","journal-title":"Exp Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.066","article-title":"Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study","volume":"80","author":"Mrowietz","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15860","article-title":"Remission of anti-tumor necrosis factor-\u03b1 antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis","volume":"48","author":"Imafuku","year":"2021","journal-title":"J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15176","article-title":"Response of palmoplantar pustulosis to upadacitinib: A case series of five patients","volume":"21","author":"Rahbar Kooybaran","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1476793","article-title":"Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients","volume":"11","author":"Du","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25259\/IJDVL_751_2024","article-title":"Clinical efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis: A single-center retrospective study","author":"Zheng","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14142","article-title":"Palmoplantar pustulosis successfully treated with upadacitinib: Report of three cases","volume":"64","author":"Gaiani","year":"2023","journal-title":"Australas J Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2280508","DOI":"10.1080\/09546634.2023.2280508","article-title":"Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib","volume":"34","author":"Zhang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17046","article-title":"Treatment of severely itchy scalp psoriasis and palmoplantar pustulosis with unsatisfied response to secukinumab, adalimumab or ustekinumab using upadacitinib: A report of two cases","volume":"51","author":"Hu","year":"2024","journal-title":"J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1476584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T06:46:36Z","timestamp":1741589196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1476584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1476584"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1476584","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"article-number":"1476584"}}